APO Research
Talk to an analyst

APO RESEARCH · REPORT

Follicular Lymphoma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Follicular Lymphoma Drugs Market Outlook and Growth Opportunities 2026

29 December 2025205 pages

Choose your research edition.

Industry ResearchFollicular Lymphoma Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Follicular Lymphoma Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Follicular Lymphoma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Follicular Lymphoma Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Follicular Lymphoma Drugs Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global Follicular Lymphoma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Follicular Lymphoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Follicular Lymphoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Follicular Lymphoma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Follicular Lymphoma Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Follicular Lymphoma Drugs market include Eisai, Teva, Novartis, Roche, Pfizer, FOSUNKite, Bayer, Beigene and Secura Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Follicular Lymphoma Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Follicular Lymphoma Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Follicular Lymphoma Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Follicular Lymphoma Drugs market.

Follicular Lymphoma Drugs Segment by Company

Eisai

Teva

Novartis

Roche

Pfizer

FOSUNKite

Bayer

Beigene

Secura Bio

MundiPharma

JW Therapeutics

Gilead Sciences

Epizyme

Eagle Pharmaceuticals

Bristol-Myers Squibb

Acrotech Biopharma

Follicular Lymphoma Drugs Segment by Type

Anti-CD20 mAbs

Kinase Inhibitor

Chemotherapy Agents

Others

Follicular Lymphoma Drugs Segment by Application

Injection

Oral

Follicular Lymphoma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Follicular Lymphoma Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Follicular Lymphoma Drugs key companies, revenue, market share, and recent developments.

3. To split the Follicular Lymphoma Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Follicular Lymphoma Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Follicular Lymphoma Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Follicular Lymphoma Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Follicular Lymphoma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Follicular Lymphoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Follicular Lymphoma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Follicular Lymphoma Drugs industry.

Chapter 3: Detailed analysis of Follicular Lymphoma Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Follicular Lymphoma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Follicular Lymphoma Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Follicular Lymphoma Drugs Industry Trends Table 2. Follicular Lymphoma Drugs Industry Drivers Table 3. Follicular Lymphoma Drugs Industry Opportunities and Challenges Table 4. Follicular Lymphoma Drugs Industry Restraints Table 5. Global Follicular Lymphoma Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Follicular Lymphoma Drugs Revenue Share by Company (2021-2026) Table 7. Global Follicular Lymphoma Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Follicular Lymphoma Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Follicular Lymphoma Drugs Company, Product Type & Application Table 10. Global Follicular Lymphoma Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Follicular Lymphoma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Anti-CD20 mAbs Table 15. Significant Companies of Kinase Inhibitor Table 16. Significant Companies of Chemotherapy Agents Table 17. Significant Companies of Others Table 18. Global Follicular Lymphoma Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Follicular Lymphoma Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Follicular Lymphoma Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Follicular Lymphoma Drugs Sales Value Share by Type (2021-2026) Table 22. Global Follicular Lymphoma Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Injection Table 24. Significant Companies of Oral Table 25. Global Follicular Lymphoma Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Follicular Lymphoma Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Follicular Lymphoma Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Follicular Lymphoma Drugs Sales Value Share by Application (2021-2026) Table 29. Global Follicular Lymphoma Drugs Sales Value Share by Application (2027-2032) Table 30. Global Follicular Lymphoma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Follicular Lymphoma Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Follicular Lymphoma Drugs Sales Value Share by Region (2021-2026) Table 33. Global Follicular Lymphoma Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Follicular Lymphoma Drugs Sales Value Share by Region (2027-2032) Table 35. Global Follicular Lymphoma Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Follicular Lymphoma Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Follicular Lymphoma Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Follicular Lymphoma Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Follicular Lymphoma Drugs Sales Value Market Share by Country (2027-2032) Table 40. Eisai Company Information Table 41. Eisai Business Overview Table 42. Eisai Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Eisai Follicular Lymphoma Drugs Product Portfolio Table 44. Eisai Recent Development Table 45. Teva Company Information Table 46. Teva Business Overview Table 47. Teva Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Teva Follicular Lymphoma Drugs Product Portfolio Table 49. Teva Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis Follicular Lymphoma Drugs Product Portfolio Table 54. Novartis Recent Development Table 55. Roche Company Information Table 56. Roche Business Overview Table 57. Roche Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Roche Follicular Lymphoma Drugs Product Portfolio Table 59. Roche Recent Development Table 60. Pfizer Company Information Table 61. Pfizer Business Overview Table 62. Pfizer Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Pfizer Follicular Lymphoma Drugs Product Portfolio Table 64. Pfizer Recent Development Table 65. FOSUNKite Company Information Table 66. FOSUNKite Business Overview Table 67. FOSUNKite Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. FOSUNKite Follicular Lymphoma Drugs Product Portfolio Table 69. FOSUNKite Recent Development Table 70. Bayer Company Information Table 71. Bayer Business Overview Table 72. Bayer Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Bayer Follicular Lymphoma Drugs Product Portfolio Table 74. Bayer Recent Development Table 75. Beigene Company Information Table 76. Beigene Business Overview Table 77. Beigene Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Beigene Follicular Lymphoma Drugs Product Portfolio Table 79. Beigene Recent Development Table 80. Secura Bio Company Information Table 81. Secura Bio Business Overview Table 82. Secura Bio Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Secura Bio Follicular Lymphoma Drugs Product Portfolio Table 84. Secura Bio Recent Development Table 85. MundiPharma Company Information Table 86. MundiPharma Business Overview Table 87. MundiPharma Follicular Lymphoma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. MundiPharma Follicular Lymphoma Drugs Product Portfolio Table 89. MundiPharma Recent Development Table 90. JW Therapeutics Company Information Table 91. JW Therapeutics Business Overview Table 92. JW Therapeutics Follicular Lymphoma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. JW Therapeutics Follicular Lymphoma Drugs Product Portfolio Table 94. JW Therapeutics Recent Development Table 95. Gilead Sciences Company Information Table 96. Gilead Sciences Business Overview Table 97. Gilead Sciences Follicular Lymphoma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Gilead Sciences Follicular Lymphoma Drugs Product Portfolio Table 99. Gilead Sciences Recent Development Table 100. Epizyme Company Information Table 101. Epizyme Business Overview Table 102. Epizyme Follicular Lymphoma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Epizyme Follicular Lymphoma Drugs Product Portfolio Table 104. Epizyme Recent Development Table 105. Eagle Pharmaceuticals Company Information Table 106. Eagle Pharmaceuticals Business Overview Table 107. Eagle Pharmaceuticals Follicular Lymphoma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Eagle Pharmaceuticals Follicular Lymphoma Drugs Product Portfolio Table 109. Eagle Pharmaceuticals Recent Development Table 110. Bristol-Myers Squibb Company Information Table 111. Bristol-Myers Squibb Business Overview Table 112. Bristol-Myers Squibb Follicular Lymphoma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Bristol-Myers Squibb Follicular Lymphoma Drugs Product Portfolio Table 114. Bristol-Myers Squibb Recent Development Table 115. Acrotech Biopharma Company Information Table 116. Acrotech Biopharma Business Overview Table 117. Acrotech Biopharma Follicular Lymphoma Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Acrotech Biopharma Follicular Lymphoma Drugs Product Portfolio Table 119. Acrotech Biopharma Recent Development Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Follicular Lymphoma Drugs Product Image Figure 2. Global Follicular Lymphoma Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Follicular Lymphoma Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Follicular Lymphoma Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Anti-CD20 mAbs Image Figure 8. Kinase Inhibitor Image Figure 9. Chemotherapy Agents Image Figure 10. Others Image Figure 11. Global Follicular Lymphoma Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Follicular Lymphoma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Follicular Lymphoma Drugs Sales Value Share by Type (2021-2032) Figure 14. Injection Image Figure 15. Oral Image Figure 16. Global Follicular Lymphoma Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Follicular Lymphoma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Follicular Lymphoma Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Follicular Lymphoma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Follicular Lymphoma Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Follicular Lymphoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Follicular Lymphoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Follicular Lymphoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Follicular Lymphoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Follicular Lymphoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Follicular Lymphoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Follicular Lymphoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Follicular Lymphoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Follicular Lymphoma Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Follicular Lymphoma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-CD20 mAbs
  • Kinase Inhibitor
  • Chemotherapy Agents
  • Others
Applications
  • Injection
  • Oral
Companies covered
  • Eisai
  • Teva
  • Novartis
  • Roche
  • Pfizer
  • FOSUNKite
  • Bayer
  • Beigene
  • Secura Bio
  • MundiPharma
  • JW Therapeutics
  • Gilead Sciences
  • Epizyme
  • Eagle Pharmaceuticals
  • Bristol-Myers Squibb
  • Acrotech Biopharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Follicular Lymphoma Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Follicular Lymphoma Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Follicular Lymphoma Drugs Market Dynamics
  1. 2.1 Follicular Lymphoma Drugs Industry Trends
  2. 2.2 Follicular Lymphoma Drugs Industry Drivers
  3. 2.3 Follicular Lymphoma Drugs Industry Opportunities and Challenges
  4. 2.4 Follicular Lymphoma Drugs Industry Restraints
3 Follicular Lymphoma Drugs Market by Company
  1. 3.1 Global Follicular Lymphoma Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Follicular Lymphoma Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Follicular Lymphoma Drugs Company Ranking (2024-2026)
  4. 3.4 Global Follicular Lymphoma Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Follicular Lymphoma Drugs Company Product Type and Application
  6. 3.6 Global Follicular Lymphoma Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Follicular Lymphoma Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Follicular Lymphoma Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Follicular Lymphoma Drugs Market by Type
  1. 4.1 Follicular Lymphoma Drugs Type Introduction
  2. 4.1.1 Anti-CD20 mAbs
  3. 4.1.2 Kinase Inhibitor
  4. 4.1.3 Chemotherapy Agents
  5. 4.1.4 Others
  6. 4.2 Global Follicular Lymphoma Drugs Sales Value by Type
  7. 4.2.1 Global Follicular Lymphoma Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Follicular Lymphoma Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Follicular Lymphoma Drugs Sales Value Share by Type (2021-2032)
5 Follicular Lymphoma Drugs Market by Application
  1. 5.1 Follicular Lymphoma Drugs Application Introduction
  2. 5.1.1 Injection
  3. 5.1.2 Oral
  4. 5.2 Global Follicular Lymphoma Drugs Sales Value by Application
  5. 5.2.1 Global Follicular Lymphoma Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Follicular Lymphoma Drugs Sales Value by Application (2021-2032)
  7. 5.2.3 Global Follicular Lymphoma Drugs Sales Value Share by Application (2021-2032)
6 Follicular Lymphoma Drugs Regional Value Analysis
  1. 6.1 Global Follicular Lymphoma Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Follicular Lymphoma Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Follicular Lymphoma Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Follicular Lymphoma Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Follicular Lymphoma Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Follicular Lymphoma Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Follicular Lymphoma Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Follicular Lymphoma Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Follicular Lymphoma Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Follicular Lymphoma Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Follicular Lymphoma Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Follicular Lymphoma Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Follicular Lymphoma Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Follicular Lymphoma Drugs Sales Value Share by Country, 2025 VS 2032
7 Follicular Lymphoma Drugs Country-level Value Analysis
  1. 7.1 Global Follicular Lymphoma Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Follicular Lymphoma Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Follicular Lymphoma Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Follicular Lymphoma Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Follicular Lymphoma Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Follicular Lymphoma Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Follicular Lymphoma Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai
  2. 8.1.1 Eisai Company Information
  3. 8.1.2 Eisai Business Overview
  4. 8.1.3 Eisai Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Follicular Lymphoma Drugs Product Portfolio
  6. 8.1.5 Eisai Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Follicular Lymphoma Drugs Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis Follicular Lymphoma Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Roche Follicular Lymphoma Drugs Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Follicular Lymphoma Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 FOSUNKite
  32. 8.6.1 FOSUNKite Company Information
  33. 8.6.2 FOSUNKite Business Overview
  34. 8.6.3 FOSUNKite Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 FOSUNKite Follicular Lymphoma Drugs Product Portfolio
  36. 8.6.5 FOSUNKite Recent Developments
  37. 8.7 Bayer
  38. 8.7.1 Bayer Company Information
  39. 8.7.2 Bayer Business Overview
  40. 8.7.3 Bayer Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bayer Follicular Lymphoma Drugs Product Portfolio
  42. 8.7.5 Bayer Recent Developments
  43. 8.8 Beigene
  44. 8.8.1 Beigene Company Information
  45. 8.8.2 Beigene Business Overview
  46. 8.8.3 Beigene Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Beigene Follicular Lymphoma Drugs Product Portfolio
  48. 8.8.5 Beigene Recent Developments
  49. 8.9 Secura Bio
  50. 8.9.1 Secura Bio Company Information
  51. 8.9.2 Secura Bio Business Overview
  52. 8.9.3 Secura Bio Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Secura Bio Follicular Lymphoma Drugs Product Portfolio
  54. 8.9.5 Secura Bio Recent Developments
  55. 8.10 MundiPharma
  56. 8.10.1 MundiPharma Company Information
  57. 8.10.2 MundiPharma Business Overview
  58. 8.10.3 MundiPharma Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MundiPharma Follicular Lymphoma Drugs Product Portfolio
  60. 8.10.5 MundiPharma Recent Developments
  61. 8.11 JW Therapeutics
  62. 8.11.1 JW Therapeutics Company Information
  63. 8.11.2 JW Therapeutics Business Overview
  64. 8.11.3 JW Therapeutics Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 JW Therapeutics Follicular Lymphoma Drugs Product Portfolio
  66. 8.11.5 JW Therapeutics Recent Developments
  67. 8.12 Gilead Sciences
  68. 8.12.1 Gilead Sciences Company Information
  69. 8.12.2 Gilead Sciences Business Overview
  70. 8.12.3 Gilead Sciences Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Gilead Sciences Follicular Lymphoma Drugs Product Portfolio
  72. 8.12.5 Gilead Sciences Recent Developments
  73. 8.13 Epizyme
  74. 8.13.1 Epizyme Company Information
  75. 8.13.2 Epizyme Business Overview
  76. 8.13.3 Epizyme Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Epizyme Follicular Lymphoma Drugs Product Portfolio
  78. 8.13.5 Epizyme Recent Developments
  79. 8.14 Eagle Pharmaceuticals
  80. 8.14.1 Eagle Pharmaceuticals Company Information
  81. 8.14.2 Eagle Pharmaceuticals Business Overview
  82. 8.14.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Eagle Pharmaceuticals Follicular Lymphoma Drugs Product Portfolio
  84. 8.14.5 Eagle Pharmaceuticals Recent Developments
  85. 8.15 Bristol-Myers Squibb
  86. 8.15.1 Bristol-Myers Squibb Company Information
  87. 8.15.2 Bristol-Myers Squibb Business Overview
  88. 8.15.3 Bristol-Myers Squibb Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bristol-Myers Squibb Follicular Lymphoma Drugs Product Portfolio
  90. 8.15.5 Bristol-Myers Squibb Recent Developments
  91. 8.16 Acrotech Biopharma
  92. 8.16.1 Acrotech Biopharma Company Information
  93. 8.16.2 Acrotech Biopharma Business Overview
  94. 8.16.3 Acrotech Biopharma Follicular Lymphoma Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Acrotech Biopharma Follicular Lymphoma Drugs Product Portfolio
  96. 8.16.5 Acrotech Biopharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst